Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis
Paul Chervinsky(University of Pittsburgh), Howard Fox(Novartis (United Kingdom)), Thomas B. Casale(University of South Florida), Angel FowlerTaylor(Novartis (United States)), Robert G. Townley(Creighton University), S. Hedgecock(Novartis (United Kingdom)), Ita Tripathy, Henry Shen(Bristol-Myers Squibb (United States))
Cited by 214
Related Papers
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision
|Journal of Allergy and Clinical Immunology|2017|2k
An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations
|American Journal of Respiratory and Critical Care Medicine|2009|1.9k
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision
|Journal of Allergy and Clinical Immunology|2010|1.8k
Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome
|Journal of Allergy and Clinical Immunology|2011|1.2k